Jazz Pharmaceuticals plc (JAZZ) stock

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value

$241.55+1.18 (+0.49%)

Close on Nov 13, 2026Market cap $15.68BP/E 78.7Yield –

Jazz Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Jazz Pharmaceuticals's EV/EBITDA was 20.3× on Nov 11, 2026, against 18.4× a year earlier. Over the last 5 years it ranged from 13.2× to 313.2×, with a median of 29.3×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	20.3×	+2.1
2025	Jul 31, 2025	18.2×	−0.4
2024	Dec 31, 2024	18.6×	−48.6
2023	Dec 29, 2023	67.2×	+7.0
2022	Dec 30, 2022	60.1×	+15.5
2021	Dec 31, 2021	44.6×	+4.6
2020	Dec 31, 2020	40.0×	+25.5
2019	Dec 31, 2019	14.5×	−0.7
2018	Dec 31, 2018	15.3×	−2.1
2017	Dec 29, 2017	17.3×	+1.1
2016	Dec 30, 2016	16.2×	−1.7
2015	Dec 31, 2015	17.8×	−49.6
2014	Dec 31, 2014	67.5×	+42.7
2013	Dec 31, 2013	24.7×	+5.1
2012	Dec 31, 2012	19.6×	+5.2
2011	Dec 30, 2011	14.4×	−21.7
2010	Dec 31, 2010	36.1×	–

Where these numbers come from

Parsed from the XBRL in Jazz Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing